Surface-modified polymers for cardiac tissue engineering

2017 ◽  
Vol 5 (10) ◽  
pp. 1976-1987 ◽  
Author(s):  
Ambigapathi Moorthi ◽  
Yu-Chang Tyan ◽  
Tze-Wen Chung
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Cardiovascular Disease ◽  
Tissue Engineering ◽  
Causes Of Death ◽  
Cardiac Tissue ◽  
Cardiac Tissue Engineering ◽  
Modified Polymers ◽  
Surface Modified

Cardiovascular disease (CVD), leading to myocardial infarction and heart failure, is one of the major causes of death worldwide.

scholarly journals Biomaterial strategies for alleviation of myocardial infarction

2011 ◽  
Vol 9 (66) ◽  
pp. 1-19 ◽  
Author(s):  
Jayarama Reddy Venugopal ◽  
Molamma P. Prabhakaran ◽  
Shayanti Mukherjee ◽  
Rajeswari Ravichandran ◽  
Kai Dan ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Tissue Engineering ◽  
Stem Cells ◽  
Cardiac Tissue ◽  
Cardiac Tissue Engineering ◽  
Left Ventricular ◽  
World Health ◽  
Myocardial Repair ◽  
Apparent Lack

World Health Organization estimated that heart failure initiated by coronary artery disease and myocardial infarction (MI) leads to 29 per cent of deaths worldwide. Heart failure is one of the leading causes of death in industrialized countries and is expected to become a global epidemic within the twenty-first century. MI, the main cause of heart failure, leads to a loss of cardiac tissue impairment of left ventricular function. The damaged left ventricle undergoes progressive ‘remodelling’ and chamber dilation, with myocyte slippage and fibroblast proliferation. Repair of diseased myocardium with in vitro -engineered cardiac muscle patch/injectable biopolymers with cells may become a viable option for heart failure patients. These events reflect an apparent lack of effective intrinsic mechanism for myocardial repair and regeneration. Motivated by the desire to develop minimally invasive procedures, the last 10 years observed growing efforts to develop injectable biomaterials with and without cells to treat cardiac failure. Biomaterials evaluated include alginate, fibrin, collagen, chitosan, self-assembling peptides, biopolymers and a range of synthetic hydrogels. The ultimate goal in therapeutic cardiac tissue engineering is to generate biocompatible, non-immunogenic heart muscle with morphological and functional properties similar to natural myocardium to repair MI. This review summarizes the properties of biomaterial substrates having sufficient mechanical stability, which stimulates the native collagen fibril structure for differentiating pluripotent stem cells and mesenchymal stem cells into cardiomyocytes for cardiac tissue engineering.

Development of functional hydrogels for heart failure

2019 ◽  
Vol 7 (10) ◽  
pp. 1563-1580 ◽  
Author(s):  
Yanxin Han ◽  
Wenbo Yang ◽  
Wenguo Cui ◽  
Ke Yang ◽  
Xiaoqun Wang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Tissue Engineering ◽  
Cardiac Tissue ◽  
Cardiac Tissue Engineering ◽  
Myocardial Regeneration ◽  
Functional Studies

Hydrogel-based approaches were reviewed for cardiac tissue engineering and myocardial regeneration in ischemia-induced heart failure, with an emphasis on functional studies, translational status, and clinical advancements.

scholarly journals Chitosan as Functional Biomaterial for Designing Delivery Systems in Cardiac Therapies

Gels ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. 253
Author(s):  
Bhaumik Patel ◽  
Ravi Manne ◽  
Devang B. Patel ◽  
Shashank Gorityala ◽  
Arunkumar Palaniappan ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Tissue Engineering ◽  
Stem Cells ◽  
Cardiac Tissue ◽  
Mechanical Stability ◽  
Cardiac Tissue Engineering ◽  
Delivery Systems ◽  
Pharmaceutical Industries

Cardiovascular diseases are a leading cause of mortality across the globe, and transplant surgeries are not always successful since it is not always possible to replace most of the damaged heart tissues, for example in myocardial infarction. Chitosan, a natural polysaccharide, is an important biomaterial for many biomedical and pharmaceutical industries. Based on the origin, degree of deacetylation, structure, and biological functions, chitosan has emerged for vital tissue engineering applications. Recent studies reported that chitosan coupled with innovative technologies helped to load or deliver drugs or stem cells to repair the damaged heart tissue not just in a myocardial infarction but even in other cardiac therapies. Herein, we outlined the latest advances in cardiac tissue engineering mediated by chitosan overcoming the barriers in cardiac diseases. We reviewed in vitro and in vivo data reported dealing with drug delivery systems, scaffolds, or carriers fabricated using chitosan for stem cell therapy essential in cardiac tissue engineering. This comprehensive review also summarizes the properties of chitosan as a biomaterial substrate having sufficient mechanical stability that can stimulate the native collagen fibril structure for differentiating pluripotent stem cells and mesenchymal stem cells into cardiomyocytes for cardiac tissue engineering.

Analysis of Gene Expression and Morphology of P19 Cells Cultured in an Apatite-Fiber Scaffold

2012 ◽  
Vol 529-530 ◽  
pp. 370-373 ◽  
Author(s):  
Hide Ishii ◽  
Yuya Mukai ◽  
Mamoru Aizawa ◽  
Nobuyuki Kanzawa
Keyword(s):  
Heart Failure ◽  
Tissue Engineering ◽  
Cardiac Tissue ◽  
Cultured Cells ◽  
Three Dimensional ◽  
Heart Tissue ◽  
Cardiac Tissue Engineering ◽  
Cardiac Differentiation ◽  
Embryonal Carcinoma Cell ◽  
Cells Cultured

Heart disease is the second most common cause of mortality in Japan. Most cases of late stage heart failure can only be effectively treated by a heart transplant. Cardiac tissue engineering is emerging both as a new approach for improving the treatment of heart failure and for developing new cardiac drugs. Apatite-fiber scaffold (AFS) was originally designed as a substitute material for bone. AFS contains two sizes of pores and is appropriate for the three dimensional proliferation and differentiation of osteoblasts. To establish engineered heart tissue, a pluripotent embryonal carcinoma cell line, P19.CL6, was cultured in AFS. P19.CL6 cells seeded into AFS proliferated well. Generally, cardiac differentiation of P19.CL6 cells is induced by treating suspension-cultured cells with dimethyl sulfoxide (DMSO), after which the cells form spheroids. However, our results showed that P19.CL6 cells cultured in AFS differentiated into myocytes without forming spheroidal aggregates, and could be cultured for at least one month. Thus, we conclude that AFS is a good candidate as a scaffold for cardiac tissue engineering.

scholarly journals Cardiac Tissue Engineering for the Treatment of Myocardial Infarction

2021 ◽  
Vol 8 (11) ◽  
pp. 153
Author(s):  
Dongmin Yu ◽  
Xiaowei Wang ◽  
Lei Ye
Keyword(s):  
Myocardial Infarction ◽  
Tissue Engineering ◽  
Cardiac Tissue ◽  
Cardiac Tissue Engineering ◽  
Therapeutic Effects ◽  
Engineering Technology ◽  
Future Directions ◽  
Cell Based Therapy ◽  
Cell Engraftment ◽  
Cardiovascular Cells

Poor cell engraftment rate is one of the primary factors limiting the effectiveness of cell transfer therapy for cardiac repair. Recent studies have shown that the combination of cell-based therapy and tissue engineering technology can improve stem cell engraftment and promote the therapeutic effects of the treatment for myocardial infarction. This mini-review summarizes the recent progress in cardiac tissue engineering of cardiovascular cells from differentiated human pluripotent stem cells (PSCs), highlights their therapeutic applications for the treatment of myocardial infarction, and discusses the present challenges of cardiac tissue engineering and possible future directions from a clinical perspective.

Abstract 181: Human Heart Valve-derived Scaffold Improves Cardiac Repair in a Murine Model of Myocardial Infarction

2015 ◽  
Vol 117 (suppl_1) ◽  
Author(s):  
Jun Li ◽  
Long Wan ◽  
Yao Chen ◽  
Zhenhua Wang ◽  
Wentian Zhang ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Tissue Engineering ◽  
Heart Valve ◽  
Murine Model ◽  
Human Heart ◽  
Cardiac Tissue ◽  
Cardiac Tissue Engineering ◽  
Cardiac Repair ◽  
Infarcted Heart

Cardiac tissue engineering using biomaterials with or without a combination of cardiac stem cell therapy offers a new therapeutic option for repairing infarcted heart. So far, cardiac tissue scaffold is designed mainly based on natural and synthetic biomaterials, which do not mimic human myocardial extracellular matrix. This raises a fundamental issue about the biocompatibility of currently used biomaterials with myocardial tissue. Here we hypothesized that human heart valve-derived scaffold (hHVS) may provide a clinically relevant novel biomaterial for cardiac repair. In this study, human heart valve tissue was sliced into 100 μm tissue sheet by frozen-sectioning and then decellularized to form the hHVS. Upon anchoring onto the hHVS, post-infarct murine BM c-kit+ cells exhibited an increased capacity for proliferation and cardiomyogenic differentiation in vitro. When used to patch infarcted heart in a murine model of myocardial infarction, either implantation of the hHVS alone or c-kit+ cell-seeded hHVS significantly improved cardiac function, as shown by transthoracic echocardiography as well as by hemodynamic measurements via a Millar catheter, and by reduced infarct size; while c-kit+ cell-seeded hHVS was even superior to the hHVS alone. Thus, we have successfully developed a hHVS for cardiac repair. Our in vitro and in vivo observations provide the first evidence for translating the hHVS-based cardiac tissue engineering into clinical strategies to treat myocardial infarction.

Sign in / Sign up

Export Citation Format

Share Document